Vericel (VCEL) Net Income (2010 - 2026)
Vericel (VCEL) posted Net Income of $1.8 million for Q2 2026, up 125.78% sequentially from -$6.8 million in Q1 2026, and up 276.83% YoY from $467849.6 in Q2 2025.
Vericel (VCEL) Net Income (2010 - 2026) Analysis & Trends
Vericel has reported Net Income for 17 years, with the latest figure at $1.8 million in Q2 2026.
- Quarterly Net Income rose 276.83% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.8 million (up 271.21% YoY) and the FY2025 annual result came in at $16.5 million, up 59.41% from the prior year.
- Net Income climbed to $1.8 million in Q2 2026 per VCEL's latest filing, from -$6.8 million in the prior quarter.
- Over five years, Net Income peaked at $23.3 million in Q4 2025 and troughed at -$164.4 million in Q2 2023.
- A 5-year average of -$8.9 million and a median of -$4.0 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2025: Net Income slumped 1734.33% in 2023, then jumped 614.21% in 2025.
- Over 5 years, Net Income stood at $5.9 million in 2022, then surged by 119.4% to $13.0 million in 2023, then soared by 52.44% to $19.8 million in 2024, then rose by 17.47% to $23.3 million in 2025, then sank by 92.42% to $1.8 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered $1.8 million, -$6.8 million, and $23.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Mar 31, 2026 | -6.84 Mn |
| Dec 31, 2025 | 23.27 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | -997,000.00 |
| Mar 31, 2025 | -11.76 Mn |
| Dec 31, 2024 | 19.81 Mn |
| Sep 30, 2024 | -901,000.00 |
| Jun 30, 2024 | -5.15 Mn |
| Mar 31, 2024 | -4.33 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | -3.66 Mn |
| Jun 30, 2023 | -55.88 Mn |
| Mar 31, 2023 | -7.96 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | -4.93 Mn |